Skip to main content

Table 4 Distribution of pathogens in patients with coinfections

From: Clinical characteristics, risk factors and antiviral treatments of influenza in immunosuppressed inpatients in Beijing during the 2015–2020 influenza seasons

Patient No

Bacteria (Sample type)

Fungi (Sample type)

Viruses (Blood nucleic acid)

7

Enterococcus faecium (Blood)

  

12

 

Aspergillus spp.(BAL + GM + chest CT)

Cytomegalovirus

14

Stenotrophomonas maltophilia (Qualified sputum)

  

20

Escherichia coli and Enterococcus faecium (Ascites)

  

23

 

Aspergillus spp.(BAL + GM + chest CT)

Parainfluenza virus and Cytomegalovirus

26

Streptococcus (Qualified sputum)

  

35

Escherichia coli, Klebsiella pneumoniae and Enterococcus faecium (Ascites)

  

43, 68

Escherichia coli (Blood)

  

61, 111

  

Cytomegalovirus

62, 75

  

Cytomegalovirus and Epstein–Barr virus

63

Klebsiella pneumoniae and Pseudomonas aeruginosa (Blood)

 

Epstein–Barr virus

65

  

Herpes simplex virus

74

Klebsiella pneumoniae (Blood)

 

Cytomegalovirus

77

  

Epstein–Barr virus

85

  

JC virus

99

Stenotrophomonas maltophilia and Enterococcus faecium (Ascites)

  

103

Escherichia coli (Blood and urine)

  

109

MRSA (Blood)

 

Cytomegalovirus and BK polyomavirus

  1. BAL: bronchoalveolar lavage fluid; GM: galactomannan; MRSA: methicillin-resistant Staphylococcus aureus